FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1584314654> ?p ?o ?g. }

• W1584314654 endingPage "91" @default.
• W1584314654 startingPage "3387" @default.
• W1584314654 abstract "Epidemiological and model studies with laboratory animals have provided evidence that nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer. Sulindac, a nonsteroidal anti-inflammatory drug, has been shown to inhibit azoxymethane (AOM)-induced colon carcinogenesis in rats when administered continuously before, during, and after carcinogen treatment (initiation and postinitiation periods) or when given continuously beginning 14 weeks after carcinogen administration (promotion/ progression stage). The present study was designed to investigate the chemopreventive efficacy of sulindac sulfone (exisulind), the sulfone metabolite of sulindac, when administered during the promotion/progression stage of colon carcinogenesis in comparison to the effect during the initiation and postinitiation periods. We have also studied the modulating effect of exisulind on colonic tumor apoptosis. At 5 weeks of age, groups of male F344 rats were fed diets containing 0%, 0.06%, and 0.12% exisulind. At 7 weeks of age, groups of animals were injected s.c. with AOM (15 mg/kg body weight, once weekly for 2 weeks). Animals intended for the promotion/progression study and receiving 0% exisulind were switched to an experimental diet containing 0.12% exisulind at 14 weeks after the second AOM treatment. All rats remained on their respective dietary regimens until the termination of the study, 50 weeks after the second AOM injection. Colon tumors were evaluated histopathologically for tumor type. Administration of 0.06% and 0.12% exisulind during the initiation and postinitiation periods significantly inhibited the incidence and multiplicity of invasive and/or noninvasive adenocarcinomas of the colon. The inhibition of colon tumorigenesis by exisulind was associated with a significant retardation of body weight gain shortly after sulfone administration and increased apoptosis in the colon tumors. In contrast, administration of the higher dose (0.12%) of exisulind during the promotion/progression stage had only minimal effects on colon tumorigenesis and apoptosis in the colon tumors, suggesting that early administration, but not late administration, may be required for chemopreventive efficacy of this drug." @default.
• W1584314654 created "2016-06-24" @default.
• W1584314654 creator A5004691943 @default.
• W1584314654 creator A5009422422 @default.
• W1584314654 creator A5014024059 @default.
• W1584314654 creator A5017000224 @default.
• W1584314654 creator A5031097707 @default.
• W1584314654 creator A5048308941 @default.
• W1584314654 date "1999-07-15" @default.
• W1584314654 modified "2023-09-25" @default.
• W1584314654 title "Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process." @default.
• W1584314654 cites W1546894543 @default.
• W1584314654 cites W1598425863 @default.
• W1584314654 cites W1648593433 @default.
• W1584314654 cites W1868796410 @default.
• W1584314654 cites W1925690329 @default.
• W1584314654 cites W1928411162 @default.
• W1584314654 cites W1943726195 @default.
• W1584314654 cites W1976128207 @default.
• W1584314654 cites W2014034874 @default.
• W1584314654 cites W2026307857 @default.
• W1584314654 cites W2026831500 @default.
• W1584314654 cites W2032122995 @default.
• W1584314654 cites W2043707891 @default.
• W1584314654 cites W2051686420 @default.
• W1584314654 cites W2069782367 @default.
• W1584314654 cites W2082829435 @default.
• W1584314654 cites W2084647545 @default.
• W1584314654 cites W2097620342 @default.
• W1584314654 cites W2100283599 @default.
• W1584314654 cites W2101721166 @default.
• W1584314654 cites W2115522061 @default.
• W1584314654 cites W2122953993 @default.
• W1584314654 cites W2135938816 @default.
• W1584314654 cites W2145925849 @default.
• W1584314654 cites W2161376238 @default.
• W1584314654 cites W2167555569 @default.
• W1584314654 cites W2170720047 @default.
• W1584314654 cites W223326267 @default.
• W1584314654 cites W2318925269 @default.
• W1584314654 cites W2330709704 @default.
• W1584314654 cites W2336215030 @default.
• W1584314654 cites W2339665353 @default.
• W1584314654 cites W2422250357 @default.
• W1584314654 cites W562678055 @default.
• W1584314654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10416599" @default.
• W1584314654 hasPublicationYear "1999" @default.
• W1584314654 type Work @default.
• W1584314654 sameAs 1584314654 @default.
• W1584314654 citedByCount "48" @default.
• W1584314654 countsByYear W15843146542012 @default.
• W1584314654 countsByYear W15843146542013 @default.
• W1584314654 countsByYear W15843146542014 @default.
• W1584314654 countsByYear W15843146542015 @default.
• W1584314654 countsByYear W15843146542016 @default.
• W1584314654 countsByYear W15843146542017 @default.
• W1584314654 countsByYear W15843146542019 @default.
• W1584314654 countsByYear W15843146542021 @default.
• W1584314654 crossrefType "journal-article" @default.
• W1584314654 hasAuthorship W1584314654A5004691943 @default.
• W1584314654 hasAuthorship W1584314654A5009422422 @default.
• W1584314654 hasAuthorship W1584314654A5014024059 @default.
• W1584314654 hasAuthorship W1584314654A5017000224 @default.
• W1584314654 hasAuthorship W1584314654A5031097707 @default.
• W1584314654 hasAuthorship W1584314654A5048308941 @default.
• W1584314654 hasConcept C114246631 @default.
• W1584314654 hasConcept C121608353 @default.
• W1584314654 hasConcept C126322002 @default.
• W1584314654 hasConcept C185592680 @default.
• W1584314654 hasConcept C2776241388 @default.
• W1584314654 hasConcept C2778452354 @default.
• W1584314654 hasConcept C2778484676 @default.
• W1584314654 hasConcept C2779107934 @default.
• W1584314654 hasConcept C2780122803 @default.
• W1584314654 hasConcept C526805850 @default.
• W1584314654 hasConcept C55493867 @default.
• W1584314654 hasConcept C555283112 @default.
• W1584314654 hasConcept C71924100 @default.
• W1584314654 hasConcept C90924648 @default.
• W1584314654 hasConcept C98274493 @default.
• W1584314654 hasConceptScore W1584314654C114246631 @default.
• W1584314654 hasConceptScore W1584314654C121608353 @default.
• W1584314654 hasConceptScore W1584314654C126322002 @default.
• W1584314654 hasConceptScore W1584314654C185592680 @default.
• W1584314654 hasConceptScore W1584314654C2776241388 @default.
• W1584314654 hasConceptScore W1584314654C2778452354 @default.
• W1584314654 hasConceptScore W1584314654C2778484676 @default.
• W1584314654 hasConceptScore W1584314654C2779107934 @default.
• W1584314654 hasConceptScore W1584314654C2780122803 @default.
• W1584314654 hasConceptScore W1584314654C526805850 @default.
• W1584314654 hasConceptScore W1584314654C55493867 @default.
• W1584314654 hasConceptScore W1584314654C555283112 @default.
• W1584314654 hasConceptScore W1584314654C71924100 @default.
• W1584314654 hasConceptScore W1584314654C90924648 @default.
• W1584314654 hasConceptScore W1584314654C98274493 @default.
• W1584314654 hasIssue "14" @default.
• W1584314654 hasLocation W15843146541 @default.
• W1584314654 hasOpenAccess W1584314654 @default.

• next